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Abstract
Background: Influenza A virus is controlled with yearly vaccination while emerging global pandemics are kept at
bay with antiviral medications. Unfortunately, influenza A viruses have emerged resistance to approved influenza
antivirals. Accordingly, there is an urgent need for novel antivirals to combat emerging influenza A viruses resistant
to current treatments. Conserved viral proteins are ideal targets because conserved protein domains are present in
most, if not all, influenza subtypes, and are presumed less prone to evolve viable resistant versions. The threat of an
antiviral resistant influenza pandemic justifies our study to identify and characterize antiviral targets within influenza
proteins that are highly conserved. Influenza A nucleoprotein (NP) is highly conserved and plays essential roles
throughout the viral lifecycle, including viral RNA synthesis.
Methods: Using NP crystal structure, we targeted accessible amino acids for substitution. To characterize the NP
proteins, reconstituted viral ribonucleoproteins (vRNPs) were expressed in 293 T cells, RNA was isolated, and
reverse transcription – quantitative PCR (RT-qPCR) was employed to assess viral RNA expressed from
reconstituted vRNPs. Location was confirmed using cellular fractionation and western blot, along with
observation of NP-GFP fusion proteins. Nucleic acid binding, oligomerization, and vRNP formation, were
each assessed with native gel electrophoresis.
Results: Here we report characterization of an accessible and conserved five amino acid region within the NP
body domain that plays a redundant but essential role in viral RNA synthesis. Our data demonstrate substitutions in
this domain did not alter NP localization, oligomerization, or ability to bind nucleic acids, yet resulted in a defect in viral
RNA expression. To define this region further, single and double amino acid substitutions were constructed and
investigated. All NP single substitutions were functional, suggesting redundancy, yet different combinations of two
amino acid substitutions resulted in a significant defect in RNA expression, confirming these accessible amino acids in
the NP body domain play an important role in viral RNA synthesis.
Conclusions: The identified conserved and accessible NP body domain represents a viable antiviral target to counter
influenza replication and this research will contribute to the well-informed design of novel therapies to combat
emerging influenza viruses.
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Background
Influenza A viruses cause seasonal respiratory infections
that lead to many hospitalizations and deaths each year.
The Influenza A virus genome is comprised of eight
negative sense single stranded RNA (vRNA) segments.
Humans, avians, and swine are all susceptible to influenza
A virus. Cases of direct avian to human transmission are
rare [1] because humans and avians are susceptible to
specific subtypes of influenza A virus [2]. Pigs however,
are susceptible to infection with human, avian, and swine
influenza subtypes, allowing for the mixing of genomic
segments between various subtypes of the virus and the
potential for a new pandemic influenza A subtype to
emerge. Genome reassortment through segment mixing
can yield new Influenza A subtypes of varying transmissi-
bility and pathogenicity. Reassortant viruses have the
potential to cause human pandemics, as seen in 1918,
1957, 1968, and most recently 2009 [3].
Annual vaccines are used to help protect against sev-
eral subtypes of the Influenza A virus and two subtypes
of Influenza B. However, because vaccine production
takes months, circulating viruses can mutate and reas-
sort while vaccine production is ongoing, resulting in
decreased vaccine effectiveness. Indeed, both mutation
and reassortment of influenza genes reduce efficacy of
yearly vaccines; resulting in at best 23% vaccine effective-
ness according to the CDC [4]. It was recently reported
that the nasal spray vaccine known as FluMist was inef-
fective and did not offer protection from the virus, with
the CDC’s Advisory Committee on Immunization Prac-
tices (ACIP) voting down live attenuated influenza vaccine
(LAIV) for use during the 2016–2017 season [5]. Simi-
larly, due to the production time required to generate
vaccines, they are not an option to protect against newly
emerging subtypes of influenza virus, as seen in 2009 with
the novel H1N1 pandemic. Once infection has occurred,
antiviral drugs are taken to aid in recovery and antiviral
drugs were essential to slow the spread of the 2009 pan-
demic [6]. Current antivirals fall under two categories,
neuraminidase inhibitors (oseltamivir and zanamivir) and
M2 ion channel blockers (amantadine and rimantadine).
The drugs targeting the M2 ion channel are no longer effi-
cacious due to resistance that has developed within the
circulating strains of influenza. The widely publicized anti-
viral drug Tamiflu (oseltamivir) is still in use, although
gene segments encoding resistance are in circulation as
there have been a small number of viral subtypes found to
be resistant to treatment with Tamiflu [7]. Other evidence
demonstrates resistance to oseltamivir can be selected for
during treatment [8–11]. Continued use of Tamiflu and
other neuraminidase inhibitors will select for emergence
of resistant strains and it is possible neuraminidase inhibi-
tors will lose effectiveness and no longer be of use, as
observed with the M2 ion channel inhibitors. With the
potential of a dangerous influenza pandemic arising, new
antiviral drugs targeting conserved regions of the virus are
urgently needed [12].
The Influenza A virus utilizes eight genomic seg-
ments to encode at least ten mRNAs through alternate
splicing [13] and yield greater than twelve proteins
through alternate translation [14–17]. There are two
viral surface proteins, HA and NA, for which the in-
fluenza subtypes are named. The RNA dependent
RNA polymerase (RdRP) complex is comprised of
three proteins: PB1, PB2, and PA. Nucleoprotein (NP)
binds the single stranded genome segments and inter-
acts with the RdRP to form the viral ribonucleoprotein
(vRNP), responsible for RNA synthesis (Fig. 1a). The
remaining two segments are M and NS, which are
alternately spliced to form M1, M2, NS1, and NS2
(NEP) proteins.
Upon infection the eight vRNPs are transported to the
nucleus to transcribe and replicate the vRNA. The PB2
subunit contains the active site that binds to the host
pre-mRNA [18] while the PA subunit of the polymerase
complex cleaves a cellular capped-mRNA primer from
host mRNA to initiate transcription [19–21]. The PB1
subunit uses this short, capped host RNA to carry out
polymerization of the viral mRNA transcript. Termin-
ation of transcription occurs when the polymerase
reaches a repetitive sequence of U residues and stutters,
which produces a poly(A) tail [22]. Viral replication off
the vRNA template results a full-length complementary
(cRNA) intermediate, which is then replicated to yield
progeny vRNA.
NP is more than just a structural component of the
vRNP as NP interacts with both viral [23, 24] and host
factors [25–29] to regulate viral RNA expression. Fifty-
nine percent of NP residues are highly conserved
among influenza A isolates [30] making NP interactions
compelling antiviral targets [12]. NP is comprised of
two main regions referred to as the head domain and
the body domain (Fig. 1b). In between the head and
body domain is a positively charged RNA binding
groove. The negatively charged phosphate backbone of
viral vRNA and cRNA forms ionic bonds with the
arginine-rich groove and contributes to the overall
shape of the vRNP [31]. Opposite the RNA binding
groove is the portion of the protein referred to as the
tail loop. NP monomers undergo oligomerization
through this tail loop consisting of a salt bridge be-
tween residues 339 and 416 on different NP monomers
[32–34]. NP oligomerization is strengthened by RNA
binding and is essential for the formation of functional
vRNPs [34]. NP also directly interacts with components
of the RdRP including PB1 and PB2 [32, 35]. Several
groups have identified the body domain of NP as a site of
interaction with PB2 [32, 35, 36].
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Here we characterize mutations within 5 amino
acids of NP that comprise an accessible region of the
NP body domain, as determined by NP crystal struc-
ture [32]. This region was selected for mutagenesis to
target interaction between NP and RdRP [35]. The
amino acids that were substituted were chosen based
on relative sequence conservation and accessibility in
regards to the surface of the protein determined by
examining the cryo-electron microscopy (cryo-EM)
structure of mini-vRNPs [37] and monomer NP crys-
tal structure [32] analyzed for side chain accessibility
using Deep View-Swiss-PdbViewer 4.0. Five glycine
substitutions were sufficient to completely shut down
NP function in viral RNA synthesis. Despite these
findings, single glycine substitutions within this region
were as functional as wild type NP. Double mutants
in this region exhibited partial activity, indicating that
this surface is likely comprised of several amino acids
important for interaction in functional vRNPs. Our
findings highlight this conserved NP domain as an
important interaction surface essential for viral RNA
synthesis and support further investigation of antiviral
drugs that target this region of NP.
Methods
Cells
293 T Human embryonic kidney cells were grown in a
water-jacketed incubator with 5% CO2 output at 37 °C.
The cell line was purchased from ATCC.
Plasmids
pcDNA NP-FLAG, PA, PB1, PB2 plasmids were used to
encode Influenza A/Udorn/307/72 (H3N2) mRNA to
drive expression of the viral proteins required for vRNP
formation. NP is fused to a C-terminal 1X FLAG epitope
tag and results in functional vRNPs and cRNPs [38].
pHH21 GFP-M vRNA and pHH21 M cRNA plasmids
were used to express either GFP-M vRNA (- sense) or
M cRNA (+ sense) to complete vRNP or cRNP expres-
sion. The expressed M cRNA or GFP-M vRNA must be
processed by the viral polymerase ribonucleoprotein to
be expressed as mRNA for translation to protein.
For this study, sixteen plasmids to express the different
NP glycine substitution and two plasmids to express NP
GFP fusion proteins were constructed by two-step PCR.
Briefly, in the first step, two individual PCR reactions
generated two fragments with complementary ends. A
Fig. 1 Components of the Viral Ribonucleoprotein and Nucleoprotein. a Graphical illustration of the viral Ribonucleoprotein (vRNP) complex,
comprised of the viral polymerase subunits, PB1, PB2, and PA, bound to both the 5′ and 3′ ends of the viral RNA segment, and multiple copies of
nucleoprotein (NP). b Domains of Nucleoprotein monomer crystal structure [32] using Deep View-Swiss-PdbViewer 4.0, with head domain, body
domain, RNA pocket, and tail loop regions labeled. c. Nucleoprotein body domain substitutions of NPbd3 using Deep View-Swiss-PdbViewer
4.0 to analyze the accessible residues in the body domain of the NP monomer crystal structure [32]. In both b and c, residue color represents
accessibility within the NP monomer as determined by the Deep View-Swiss-PdbViewer 4.0 “color” tool, with greatest to least accessible as
follows: red, orange, yellow, green, light blue, and dark blue. Residues 289, 293, 294, 308, and 309 mutated in NPbd3 are highlighted in C.
d Nucleoprotein (NP) sequence alignment from select influenza subtypes using CLS freeware and amino acids 281-310. Colors correlate with
amino acid property. Asterisks indicate NPbd3 mutant
Davis et al. Virology Journal  (2017) 14:22 Page 3 of 13
second PCR reaction combined the two fragments to
generate the entire portion of DNA and include restric-
tion enzyme sites for digestion and ligation into the
pcDNA3 vector. Constructed plasmids were sequenced
confirmed by Retrogen.
DNA transfection
Plasmid mixtures to express reconstituted vRNPs and
cRNPs were prepared including pcDNA PB1, pcDNA
PB2, pcDNA PA, and pcDNA WT NP-FLAG, pcDNA
Vector (no NP), or NP mutant along with pHH21 GFP-
MvRNA or McRNA to express vRNA or cRNA respect-
ively. RNAs must be processed by the viral polymerase
ribonucleoprotein to be expressed as mRNA for transla-
tion to protein. Additional experiments transfected sin-
gle plasmids at suggested concentration per culture dish.
In all cases, DNA was transfected with Trans-IT reagent
(DNA to reagent ratio of 1:3) as per manufacturer’s
directions. Cells were incubated in a tissue culture incu-
bator for 48 h using either 6-well dishes or 100 mm
dishes as appropriate for experiment.
GFP visualization representing reconstituted vRNP and
cRNP activity
Cells were observed for GFP-M expression 48 h post-
transfection. WT NP served as positive control while no
NP is negative control. GFP was visualized with a Nikon
Eclipse TS100 (Nikon Intensilight C-HGFI for fluores-
cence) inverted microscope and images captured with the
Nikon DS-Qi1Mc camera with NS Elements software.
Cell collection
Forty-eight hours post-transfection cells were collected and
pelleted by centrifugation. Proteins were isolated through
either total protein isolation or cellular fractionation.
Total protein isolation
Cell pellets were resuspended in RIPA Lysis Buffer
(25 mM HCl pH 7.6, 150 mM NaCl, 1% deoxycholate,
0.1% SDS) containing protease inhibitors and lysed using
a Fisher Scientific Sonic Dismembrator for 10 pulses at
30%, output 3–4. Soluble protein extract was clarified with
high-speed centrifugation to pellet debris. Proteins were
denatured using 1X SDS protein loading dye and heat at
95 °C for five minutes. Proteins were separated on a 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS PAGE) and transferred to nitrocellulose.
Cellular fractionation
Cells were fractionated using 0.2% NP-40 non-ionic
detergent in RSB to break open cellular plasma mem-
brane while keeping the nuclear membranes intact. Mi-
croscopy was used to confirm disrupted plasma
membranes and intact nuclei. The nuclei were pelleted
by centrifugation, resuspended in RSB, and sonicated for
30 pulses at 30% to bust the nuclear membrane. Both
nuclear and cytoplasmic fractions were clarified by high-
speed centrifugation.
Western blot
All NP constructs encode a FLAG epitope tag at the C-
terminus and were detected using anti-FLAG antibody
(Agilent). Anti-tubulin antibody (Abcam) was used to
confirm protein loading when evaluating total protein.
Anti-Hsp90 antibody (Abcam) to detect Hsp90, a
protein localized in the cytoplasm, serves as con-
firmation of cellular fractionation. Pierce ECL reagents
(Thermo Scientific) were used to develop blots and
images were captured using a Chemidoc XRS imager
(Bio-Rad) with Quantity One software.
Immunopurification
The nuclear fraction of cells transfected with WT-NP,
NPbd3, or No NP were incubated with Anti- FLAG M2
Affinity Gel agarose beads (Sigma-Aldrich), incubated
overnight at 4 °C with rotation, washed five times in
RSB (reticulocyte standard buffer: 10 mM Tris HCl
pH 7.5, 10 mM KCl, 1.5 mM MgCl2) + 0.2% NP-40, and
eluted for 1 h at room temperature with 150 ng/ul 3X
FLAG peptide (APEXBIO).
Electrophoretic mobility shift assay (EMSA)
Similar volume of immunopurified proteins were incu-
bated with 20 picomoles of biotin labeled ssDNA for
20 min at room temperature and mixed with 2.5% glycerol
for loading. The protein-DNA samples were run on an 8%
TBE non-denaturing PAGE in 4 °C, followed by transfer to
nitrocellulose and Western blotting. The membrane was
probed with Streptavadin-HRP (1:3000) and Pierce ECL
reagents were used to detect the biotin labeled ssDNA.
Blue native polyacrylamide gel electrophoresis (BN-PAGE)
Total protein from WT-NP, NPbd3, or no NP trans-
fected cells were run on a 6% 1D Blue Native PAGE
while total protein from cells expressing reconstituted
vRNPs was run on a gradient of 4–13% 1D Blue Native
PAGE. Resolved complexes were transferred on to nitro-
cellulose and blots were probed with anti-FLAG to
detect WT-NP and NPbd3.
GFP fusion protein location
Plasmids expressing NP-GFP, NPbd3-GFP, or eGFP were
transfected into 293 T cells grown on poly-L-Lysine
cover slips. 48 h post transfection the cells were washed
and fixed using a 1:1 methanol and acetone mixture.
The coverslips were mounted onto glass slides using
SouthernBiotech™ DAPI-Fluoromount-G™ Clear Mount-
ing Media, which stains the cell nucleus blue. Slides were
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observed on a Nikon ECLIPSE TE2000-U fluorescent
microscope and images were captured with an Andor
Clara DR-3446 camera using NIS-Elements AR software.
RNA isolation
Total RNA was isolated with Trizol (Invitrogen), follow-
ing the manufacturer’s protocol. RNA concentration and
purity of samples was determined at OD260 and OD280
using a NanoDrop ND1000 Nanospectrophotometer
(Thermo Fischer Scientific). Integrity of rRNA was
evaluated on a 1% bleach/1% agarose gel [39].
RTqPCR
2.5 micrograms (μg) of RNA was DNase treated. 1 μg
was reverse transcribed using Promega AMV reverse
transcription system following the manufacturer’s proto-
col. 1 μg was used in the negative control reaction, lack-
ing the AMV reverse transcriptase enzyme to control for
DNA contamination. Oligo dT (mRNA) or vRNA spe-
cific primers (vRNA) were used in the RT reaction to
produce cDNA. Real time quantitative PCR using an
Applied Biosystems SYBR Select Master Mix was
performed on cDNA with primers targeting the influ-
enza M gene. qPCR reactions were carried out in tripli-
cate using the AB Step One qPCR machine. Significance
was evaluated through t-test by comparing WT NP
with no NP or NPbd3 both reporting significance
with p-values <0.02.
Results
Mutational analysis of nucleoprotein domains
Accessible regions of the RNA binding pocket, head
domain, and body domain were examined by amino acid
substitutions created through cloning. Accessibility was
characterized using the Deep View Swiss PdbViewer
“color” toolbar. The RNA binding pocket mutant,
NPrbp1, encoded R152A while the head domain mutant,
NPhd1 was altered at amino acids R213A and K214A.
Five regions of the NP body domain were investigated
through the following mutants: NPbd1 (E46A, K48A),
NPbd2 (D101A), NPbd3 (Y289G, K293G, E294G,
Q308G, N309G), NPbd4 (S482A), and NPbd5 (S467G,
E469G, N470G, T471G, and N472G). Both Alanine and
Glycine are used in substitution analysis to remove inter-
acting side groups.
Activity of each NP mutant was tested using the
reconstituted viral ribonucleoprotein (vRNP) expression
system (Fig. 2). Plasmids to express mRNA encoding
PB1, PB2, PA, and either NP, no NP, or NP mutant, were
transfected into 293 T cells along with plasmid to
express Green Fluorescent Protein (GFP) M vRNA, the
negative sense vRNA segment of the reconstituted
vRNP. GFP positive cells within this system represent
viral gene expression. GFP expression was observed 48 h
post transfection. All NP mutants expressed GFP at
similar levels as wild type NP (WT-NP) except NPbd3,
the third of five body domains mutants constructed
(Table 1 and Fig. 3a). NPbd3 was investigated further.
We next examined the activity of reconstituted vRNPs
comprised of NPbd3 at the level of RNA. We confirm
the defect in viral protein expression observed with
NPbd3 is reflected at the RNA level. To directly examine
both viral plus sense RNA synthesis (c/mRNA) and the
second step in replication, negative sense RNA synthesis
(vRNA), the reconstituted expression system was carried
out with either an influenza M cRNA or M vRNA tem-
plate. RNA was isolated from cells, DNAse treated,
reverse transcribed with oligo dT (vRNA template) or
vRNA specific primer (cRNA template), and subjected
to qPCR analysis targeting the M gene. NPbd3 was
found to be defective for viral c/mRNA synthesis and
vRNA synthesis compared to WT NP (Fig. 3b and c).
Characterization of NP body domain mutant #3
Conservation
To analyze the peptide sequence conservation of this
domain, we utilized analysis tools from the Influenza
Research Database, a resource containing “all genomic
and proteomic data available in public repositories for in-
fluenza viruses” [40]. We first ran analysis for sequence
variation and confirmed that these 5 amino acids are
highly conserved in human influenza viruses. Position 289
is the least conserved with Tyrosine encoded in many in-
fluenza strains but Histidine in others. While Tyr and His
are characterized with different properties (polar versus
charged, respectively) both contain an aromatic ring struc-
ture. When examining variation at 289 in human influ-
enza subtypes, H1N1 and pandemic H1N1 preferentially
encode His while H1N2, H2N2, H3N2, H5N1, and H7N9
preferentially encode Tyr. There are only 5 sequences in
the database that are unknown at this position (Xaa), with
two others encoding Lysine (both from pH1N1), while
15,057 encode His and 11,096 encode Tyr. Position 293 is
charged conserved, with strains encoding either Arginine
or Lysine. H1N1, pH1N1, and H5N1 preferentially encode
Arg while H1N1, H2N2, H3N2 preferentially encode Ly-
sine. Only 4 sequences in the database do not encode Arg
or Lys at this position (unknown Xaa), while 15,733
encode Arg and 9824 encode Lys. Position 294 is highly
conserved, with all subtypes preferentially encoding
Glutamic acid at this position. Only 1 sequence was found
to encode Valine instead (from pH1N1), with 5 sequences
reported as unknown, and 26,154 encoding Glu. Position
308 is Glutamate in all subtypes, with just 8 sequences re-
ported as unknown and 26,153 encoding Gln. Position
309 is preferentially Asparagine in all subtypes, but does
have some variation, especially among H1N1 sequences.
H1N1 subtypes encode Asparagine in most sequences
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reported (7751) but also Ala (5),His (1),Ile (2),Ser (2), and
Thr (1559). Both H3N2 and pH1N1 also have variant
sequences reported, with Thr (2) and His (1). Overall this
position is conserved, with 24,585 encoding Asn and 1572
encoding Thr, an amino acid with similar properties to
Asn, and only 17 encoding other amino acids or unknown.
We further ran short peptide searches against the pre-
compiled IRD database for influenza A NP segments. We
found 28,365 matches to amino acids 289–294 when
searching with the sequence Yxxx[RK]E. and 39,909
matches with [YH]xxx[RK]E. For amino acids 307–310 we
found 38,085 exact matches to the sequence LQNS. Our
protein sequence analysis confirms this region of NP is
highly conserved.
Expression and localization
To ensure NPbd3 was expressed and localized as wild
type NP (WT-NP) we performed cellular fractionation
and Western blot. Cells were collected and fractionated
using non-ionic detergent and centrifugation as in mate-
rials and methods. Cellular fractions were analyzed by
Western blot using anti-FLAG to observe NP and anti-
Hsp90 to demonstrate protein localized to the cyto-
plasm. NPbd3 is expressed and localized in the nucleus
as WT-NP (Fig. 4a). To further confirm localization of
NPbd3, NP-GFP and NPbd3-GFP fusion proteins were
constructed and observed through fluorescence micros-
copy. Again NPbd3 was localized in a pattern similar to
WT-NP 48 h post transfection (Fig. 4b).
PB1 PB2 PA NP or 
Mutant 
Fig. 2 Reconstituted RNP Expression System. 293 T cells are transfected with plasmids to express mRNAs encoding the viral RdRP and NP or NP
substitution mutants, and a specific vRNA or cRNA template. Cellular RNA polymerase II drives expression of viral mRNAs from pcDNA3 plasmid
backbone while cellular RNA polymerase I drives expression of the cRNA or vRNA template from pHH21 plasmid backbone. vRNP function is
assessed by gene expression from vRNA or cRNA templates
Table 1 NP amino acid substitution analysis
NP domain targeted NP amino acid vRNP activity
NPrbp1 – RNA binding pocket R152A YES
NPbd1 – body domain E46A, K48A YES
NPbd2 – body domain D101A YES
NPbd3 – body domain Y289G, K293G, E294G, Q308G, N309G NO
NPbd4 – body domain S482A YES
NPbd5 – body domain S467G, E469G, N470G, T471G, N472G YES
NPhd1 – head domain R213A, K214A YES
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NPbd3 was expressed at a slightly lower level than
WT-NP in many of our location experiments (Fig. 4). To
verify that NP is expressed in excess in the reconstituted
vRNP assay and confirm decreased expression of NPbd3
was not responsible for the defect observed, we titrated
WT-NP expressing plasmid in transfection from 600
nanograms to 100 nanograms. As expected, lowering
plasmid amount during transfection did result in de-
creased NP protein expression (Fig. 5a). We examined
activity in the reconstituted expression system using a
GFP MvRNA template and confirm that even transfec-
tion of 100 ng DNA plasmid resulted in little change in
GFP expression (Fig. 5b). While 100 ng of NP expression
plasmid and 600 ng NPbd3 expression plasmid result in
similar NP protein expression (Fig. 5a), the two samples
do not have similar vRNP activity as represented by GFP
expression (Fig. 5b). This experiments confirms NP is in
excess in our standard reconstituted vRNP assay and
that the lower NPbd3 expression is not the cause of the
lack of vRNP activity observed.
Nucleic acid binding and oligomerization
NP binds viral RNA via the nucleic acid phosphate back
bone and through NP-NP oligomerization provides the
basic structure for the vRNP. There is one NP monomer
for approximately 24 nucleotides of RNA [32]. To con-
firm NPbd3 did not result in a defect in RNA binding,
we performed an electrophoretic mobility shift assay
(EMSA) with single stranded DNA corresponding to the
5’ and 3’ ends of the viral RNA. NP RNA binding is
blocked by saturation with single stranded DNA, dem-
onstrating both nucleic acids bind at the same nucleic
acid binding pocket [23]. WT-NP and NPbd3 were
immunopurified with FLAG antibody coupled to agarose
beads and eluted with FLAG peptide. Immunopurified
NP proteins were analyzed by SDS-PAGE and Coomas-
sie Blue stain to ensure no additional protein contami-
nants (data not shown). Incubation of purified proteins
with biotin labeled single stranded nucleic acid followed
by non-denaturing native PAGE and western blot with
HRP- Streptavidin confirmed NPbd3 bound nucleic
acids as WT-NP (Fig. 6a). Biotin ssDNA with no bound
protein was consistently not detected in our assay; it is
probable unbound ssDNA does not transfer and stay at-
tached to nitrocellulose membranes as well as that asso-
ciated with protein under our assay and detection
conditions. Although NPbd3 appears to shift more RNA
than WT-NP, this is likely a reflection of protein input
and was inconsistent in repeated trials. Furthermore,
these assays do not assess the kinetics of RNA binding
only that NPbd3 maintains nucleic acid binding as ex-
pected, given we did not alter the known RNA binding
domain. NP oligomerization is important for RNA bind-
ing and formation of functional vRNPs. To examine NP
oligomer formation, protein extracts from cells express-
ing NP or NPbd3 were separated by blue native poly-
acrylamide gel electrophoresis (BN-PAGE) followed by
western blot with anti-FLAG antibody. Results demon-
strate the ability of WT-NP and NPbd3 to form oligo-
mers (Fig. 6b). We also used blue native gel
electrophoresis to confirm high molecular weight vRNP
complexes are formed. Total protein extracts from cells
expressing vRNPs comprised of the viral RNA
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 mRNA expression from M vRNA 
Fig. 3 NPbd3 is defective for viral protein and RNA expression in reconstituted vRNPs. a Plasmids to express reconstituted vRNPs with GFP-M
vRNA and either WT-NP, no NP, or NPbd3 were transfected into 293 T cells. 48 h post transfection cells were observed for GFP-M expression. WT
NP represents the positive control while no NP is the negative control. GFP was visualized with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI
for fluorescence) inverted microscope and images captured with the Nikon DS-Qi1Mc camera with NS Elements software. b and c RNA was
purified from cells expressing reconstituted vRNPs (b) or cRNPs (c) as indicated. 1 μg was DNase treated and subject to reverse transcription with
oligo dT (b) or vRNA specific primers (c) and quantitative PCR with M gene specific primers to calculate relative M RNA expression in each sample.
Data are from triplicate trials; asterisks indicate p < 0.02
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M vRNA, and either WT-NP, no NP, or NPbd3 were
separated by blue native polyacrylamide gel electrophor-
esis (BN-PAGE) followed by western blot with anti-
FLAG antibody to detect NP containing complexes.
NPbd3 is capable of formation of high molecular weight
vRNP complexes similar to wild type NP (Fig. 6c), as
expected given NPbd3 binds nucleic acids (Fig. 6a) and
oligomerizes (Fig. 6b).
Although NPbd3 was expressed in the cell, localized as
WT-NP, found in oligomers, and bound nucleic acid in
vitro, NPbd3 was completely defective for viral RNA ex-
pression in reconstituted vRNPs and cRNPs. We next
decided to further define the important residues within
this domain of NP.
NP body domain single mutant analysis
To investigate this region of the NP body domain
further, single amino acid glycine substitution mutants
were cloned, Y289G, K293G, E294G, Q308G, and N309G.
These single mutants were analyzed for vRNP function by
assessing GFP expression using our reconstituted vRNP
expression system with GFP-M vRNA (Fig. 2). All five
single NP mutants displayed activity similar to WT-NP
(Fig. 7a). Protein analysis showed the NP single mutants
were expressed at levels similar to WT-NP (Fig. 7b). RNA
concentration and integrity was confirmed with gel elec-
trophoresis (Fig. 7c). RNA analysis of the M gene through
reverse transcription using oligo-dT primers and qPCR
revealed levels of viral mRNA expression with no statis-
tical difference compared to WT-NP (Fig. 7d). Therefore,
our analysis of NP single substitutions within this region
of the body domain revealed that all were nearly as func-
tional as WT-NP, suggesting these accessible amino acids
play a redundant role.
NP body domain double mutant analysis
We next altered pairs of amino acids within this region of
the NP body domain to further define which residues con-
tribute to the defect observed. Four body domain double
mutants were constructed, Q308G/N309G, Y289G/E294G,
Y289G/N309G, and K293G/E294G. These double mutants
were analyzed for vRNP function by assessing GFP expres-
sion using our reconstituted vRNP expression system with
GFP-M vRNA (Fig. 2). All NP double mutants showed
statistically less GFP expression than WT-NP (Fig. 8a).
Total protein analysis by western blot revealed that all NP
double mutants are expressed as WT-NP (Fig. 8b). RNA
concentration and integrity was confirmed with gel electro-
phoresis (Fig. 8c). RNA analysis of the M gene through
reverse transcription using oligo-dT primers and qPCR
revealed a significant decrease in viral c/mRNA expression
in all double mutants compared to WT-NP (Fig. 8d).
Analysis of NP double mutants supports the defect in viral
RNA expression observed with NPbd3 is likely caused by a
combination of multiple accessible amino acids in the NP
body domain.
Discussion
Substitution analysis of the NP body domain revealed a
region of five amino acids that is essential for viral gene
expression. NPbd3 encodes glycine at 5 amino acids
within an accessible region of the NP body domain.
Cellular fractionation and western blot, in addition to
NP-GFP fusions and fluorescence, confirm NPbd3 was
expressed and localized in the nucleus as WT-NP (Fig. 4).
EMSA with purified NP protein confirm NPbd3 bound
nucleic acids as WT-NP (Fig. 6a). Blue Native Gel
Electrophoresis demonstrated NPbd3 could oligomerize
and form vRNPs (Fig. 6b and c). Although NPbd3 was
expressed, localized, and bound nucleic acid as WT-NP,
we found NPbd3 was completely defective for RNA ex-
pression in reconstituted vRNPs and cRNPs as evaluated
DAPI/GFP Merge 




 WT   NP  No   WT   NP  Noa
b
 NP   bd3  NP   NP  bd3  NP 
Fig. 4 NPbd3 is expressed and localized as wild type NP. a Cells
expressing reconstituted vRNPs were collected and fractionated with
NP-40 non-ionic detergent to break open cellular plasma membrane.
Microscopy was used to confirm disrupted plasma membranes and
intact nuclei. Nuclei were pelleted by centrifugation and proteins
isolated. Proteins were separated on a 10% SDS PAGE gel and
transferred to nitrocellulose. Western was performed with anti-FLAG
to detect WT NP and NPbd3 and anti-Hsp90 to detect Hsp90, a
protein localized in the cytoplasm, which serves as confirmation of
cellular fractionation. Expected size was confirmed by comparison
with Fisher BioReagents EZ-Run protein standards. b NP-GFP and
NPbd3-GFP fusion proteins or eGFP as indicated were expressed in
cells grown on poly-L-Lysine cover slips. Cells were washed and
fixed using a 1:1 methanol and acetone mixture. The coverslips
were mounted onto glass slides using SouthernBiotech™ Dapi-
Fluoromount-G™ Clear Mounting Media which stains the cell nucleus
blue. Slides were observed on a Nikon ECLIPSE TE2000-U fluorescent
microscope and images were captured with an Andor Clara DR-3446
camera using NIS-Elements AR software
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by reverse transcription and quantitative polymerase
chain reaction (RT-qPCR).
To investigate this region of the NP body domain further,
single and double amino acid mutations were cloned. Ana-
lysis of NP single mutants revealed that all were nearly as
functional as WT-NP for RNA expression in reconstituted
vRNPs, suggesting these accessible amino acids in the NP
body domain play a redundant role (Fig. 7). However, four
different combinations of two amino acid mutations re-
sulted in NP double mutants that displayed a significant
defect in RNA expression in reconstituted vRNPs, confirm-
ing these accessible amino acids in the NP body domain
play a significant role for viral RNA synthesis (Fig. 8). The
greatest defect in mRNA synthesis observed was in double
mutant 293/294, followed by 308/309, 289/309, with 289/












100 ng No NP 
NPbd3 
600 ng 
Fig. 5 Titration of NP and reconstituted vRNP activity. 293 T cells were transfected with plasmids to express reconstituted vRNPs with GFP-M
vRNA and either WT-NP, no NP, or NPbd3 at concentrations indicated. a Total protein from titration samples was isolated at 48 h post transfection
and run on a 10% SDS PAGE and transferred to nitrocellulose. The membrane was probed with FLAG to identify NP and Tubulin as the loading control.
Expected size was confirmed by comparison with Fisher BioReagents EZ-Run protein standards. b Cells were observed for GFP-M expression 48 h post
transfection. WT-NP expressed by transfection of 400 ng plasmid is the standard concentration used in our reconstituted vRNP experiments and serves
as positive control, while no NP is the negative control. GFP was visualized with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence)
inverted microscope and images captured with the Nikon DS-Qi1Mc camera with NS Elements software
a b c
Fig. 6 NPbd3 maintains nucleic acid binding, oligmerization, and vRNP formation. a WT NP and NPbd3 were immuno purified using anti-FLAG
antibody. Purified WT NP and NPbd3 were incubated with biotin labeled single stranded DNA and separated on an 8% PAGE TBE non denaturing
gel before transfer to nitrocellulose. Biotin ssDNA was detected by interaction with Streptavidin-HRP and ECL reagents. No NP samples expressed
no NP protein and serve as negative control. b Blue Native Gel Electrophoresis was utilized to migrate protein extracts of cells expressing NP and
NPbd3 followed by western blot with anti-FLAG antibody to demonstrate NP oligomer formation. Asterisk represents Native Mark Unstained
Protein standard at 480 kDa. c Blue Native Gel Electrophoresis was utilized to migrate protein extracts of cells expressing reconstituted vRNPs
comprised of either NP or NPbd3 followed by western blot with anti-FLAG antibody to demonstrate vRNP formation. Asterisk represents Native
Mark Unstained Protein standard at 1048 kDa
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The body domain region designated for mutagenesis
in NPbd3 was selected for probable interaction with the
RdRP based on mini-replicon images [37]. Residues
K293 and E294 are charge conserved. A change to gly-
cine at either residue was not enough to inhibit vRNP
function, and therefore these residues may participate in
intermolecular ionic interactions. The tyrosine at residue
289, glutamine at residue 308, and asparagine at residue
309 are polar: substituting a glycine at two of these
residues leads to a defect in mRNA synthesis. We
hypothesize that the three amino acid residues (Y289G,
Q308G, and N309G) are redundant for NP interaction
or function with the viral RdRP, specifically PB2, and
disruption of this essential NP interaction is the explan-
ation for the RNA defect observed with mutations at
308/309 and 289/309. Evidence to support this includes
experiments in which passaged avian influenza revealed
that NP N309K change is consistently paired with
specific changes in PB2 (PB2 Q236H, E627K), which
result in avian influenza replicating more efficiently
in human host cells [36]. Future experiments will
focus on obtaining direct interaction data through
co-immunoprecipitation of our double NP substitu-
tion mutants with PB2 to biochemically confirm and
better define this interaction. Our data suggest we
have identified two different interaction surfaces on
the body domain of NP. One comprised of the ionic
interaction potential with residues K293 and E294
and the other comprised of polar interaction poten-
tial with residues Y289, Q308, and N309. This is
supported by our result with NP double substitution
mutant Y289G/E294G, which demonstrates minimal
defect in vRNP activity. This is consistent if indeed
each substitution is part of a unique interaction do-
main comprised of additional redundant amino acids
as our data indicate.
We reason that the identified residues within the
accessible body domain of NP comprise important dy-
namic NP interaction surfaces and small molecule inhib-
itors could block access to these NP interactions,
making this region a viable antiviral target. Indeed, two
amino acids within the polar interaction site of this NP

























 NP single substitution mutants: 




Fig. 7 NP body domain single amino acid substitution mutants display near wild type activity in reconstituted vRNP assay. a Cells expressing
reconstituted vRNPs with GFP-M vRNA were visualized for GFP expression with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence)
inverted microscope and images captured with the Nikon DS-Qi1Mc camera with NS Elements software. Number indicates NP single residue
mutated. b Total protein was isolated from cells expressing reconstituted vRNPs with GFP-M vRNA template and the indicated NP substitution
mutant. Total protein extract was separated on 10% SDS PAGE and transferred to nitrocellulose. WT NP, NPbd3, and NP single mutants were
detected with anti-FLAG. Anti-tubulin was used as loading control. Expected size was confirmed by comparison with Fisher BioReagents EZ-Run
protein standards. c RNA from cells expressing reconstituted vRNPs with FLAG-M vRNA and either WT NP, no NP, or NPbd3, or the single amino
acid substitution mutants were isolated and analyzed by 1% bleach/agarose gel electrophoresis. d One microgram of RNA was treated with
DNase before being reverse transcribed with oligo dT (mRNA) and analyzed through quantitative PCR with primers targeting the M gene. qPCR
reactions were carried out in triplicate. Significance was evaluated through t-test by comparing WT NP; asterisks indicate p-values <0.01
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body domain, 289 and 309, comprise a novel groove im-
plicated in binding the small molecule inhibitor nucleozin
[33]. The influenza A(H1N1)pdm09 strains contained a
rare polymorphism at residue 289 [33]. Instead of a tyro-
sine, these H1N1 strains contain a histidine at amino acid
289. Tyrosine has a large hydrophobic ring structure side
chain with a polar OH group while histidine has a smaller
and positively charged side chain. This change likely
disrupts the aromatic ring stacking between nucleozin and
the tyrosine at 289 [33]. Although NP N309K resulted in
rescue of inhibition from nucleozin, our data reveal this
genetic change is possible because N309 is part of a polar
interaction site with redundant amino acids for vRNP
function. However, our results confirm this novel groove
is essential for viral gene expression and should be consid-
ered as a viable antiviral target with improved inhibitors.
Beyond nucleozin, another compound, FA-10 showed effi-
cacy against the A(H1N1)pdm09 strains but less activity
toward wild-type WSN virus [33].
Conclusions
Our data demonstrate that optimization of compounds
targeting this domain could lead to a novel and effective





























NP double substitution mutants: 






























































Fig. 8 NP double amino acid substitution mutants display decreased activity in reconstituted vRNP assay. a Cells expressing reconstituted vRNPs
with GFP-M vRNA were visualized for GFP expression with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence) inverted microscope
and images captured with the Nikon DS-Qi1Mc camera with NS Elements software. Number indicates the two NP residues substituted with
glycine. b Total protein was isolated from cells expressing reconstituted vRNPs with GFP-M vRNA template and the indicated NP mutant. Total protein
extract was separated on 10% SDS PAGE and transferred to nitrocellulose. WT NP, NPbd3, and NP double mutants were detected with anti-FLAG. Anti-
tubulin was used as loading control. Expected size was confirmed by comparison with Fisher BioReagents EZ-Run protein standards. c RNA from cells
expressing reconstituted vRNPs with FLAG-M vRNA and either WT NP, no NP, or NPbd3, or the double amino acid mutants were isolated and analyzed
by 1% bleach/agarose gel electrophoresis. d One microgram of RNA was treated with DNase before being reverse transcribed with oligo dT (mRNA)
and analyzed through quantitative PCR with primers targeting the M gene. qPCR reactions were carried out in triplicate. Significance was evaluated
through t-test by comparing WT NP; asterisks indicate p-values <0.02
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resistant influenza subtypes. Residues within this NP do-
main are redundant for vRNP function and therefore
small molecule inhibitors cannot rely on only one resi-
due for interaction with this pocket, or escape mutants
will be likely. Instead, an inhibitor that takes advantage
of the multiple redundant interaction potentials within
this domain would make escape mutants less likely. The
work presented here has defined this domain with clar-
ity, providing evidence that the polar amino acids 289,
308, and 309 offer one target while the charged inter-
action at 293 and 294 represents a separate target; both
regions of the domain can be pursued in a combin-
ational therapeutic approach. This project demonstrates
the importance of this NP accessible domain for viral
gene expression, validating studies to identify inhibitors
of this domain to block influenza virus. The work
here supports novel antivirals targeting this conserved
NP body domain are a viable approach to counter
emerging influenza viruses as existing antivirals prove
no longer efficacious.
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